A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma

BACKGROUND: This multicentre, open-label, phase-I/randomised phase-II trial evaluated safety, pharmacokinetics, maximum-tolerated-dose (MTD) per dose-limiting toxicities (DLTs), and efficacy of nintedanib vs. sorafenib in European patients with unresectable advanced hepatocellular carcinoma (aHCC)....

Descripción completa

Detalles Bibliográficos
Autores principales: Palmer, D. H., Ma, Y. T., Peck-Radosavljevic, M., Ross, P., Graham, J., Fartoux, L., Deptala, A., Studeny, M., Schnell, D., Hocke, J., Loembé, A-B., Meyer, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943284/
https://www.ncbi.nlm.nih.gov/pubmed/29563636
http://dx.doi.org/10.1038/s41416-018-0051-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943284/
https://www.ncbi.nlm.nih.gov/pubmed/29563636
http://dx.doi.org/10.1038/s41416-018-0051-8

Ejemplares similares